Steroids in Children Hospitalized With Asthma
Primary Purpose
Asthma, Status Asthmaticus, Wheezes
Status
Terminated
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Dexamethasone
Prednisone
Sponsored by
About this trial
This is an interventional treatment trial for Asthma focused on measuring Prednisone, Dexamethasone, Asthma exacerbation, Hospitalized
Eligibility Criteria
Inclusion Criteria:
- Signed informed consent by legal guardian
- Age 2 to 18 years old
- Admission to the floor with acute asthma exacerbation.
- Received single dose of oral Dexamethasone
- Initial Pediatric Asthma Score (PAS) of 8 or higher.
Exclusion Criteria:
- Admission to PICU
- Recent steroid use (within 1 month)
- Cardiac disorder, chronic respiratory illness (BPD or CF)
- Stridor
- Bacterial Pneumonia
Sites / Locations
- Wolfson Children Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Dexamethasone
Prednisone
Arm Description
Dexamethasone arm: will receive second dose of oral Dexamethasone 0.6 mg/kg/dose max of 16 mg, 24 hour from the first dose given in emergency department.
Prednisone arm: will receive oral Prednisone 1mg/kg with max of 30 mg twice daily starting 24 hours after the Dexamethasone dose given in emergency department for 8 additional doses.
Outcomes
Primary Outcome Measures
Return to normal activity (Patient Self-Assessment Score)
Proportion of patients who have returned to normal activity
Secondary Outcome Measures
Relapse ( ED visit or unscheduled physician visit)
Proportion of patients with unscheduled primary care physician visits, emergency department or hospital admission
Albuterol use (Patient Self-Assessment Score)
Proportion of patients with of ongoing albuterol use (based on validated self-reporting tool)
Asthma symptoms (Patient Self-Assessment Score)
Patient self assessment score at 2 weeks after discharge
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02780479
Brief Title
Steroids in Children Hospitalized With Asthma
Official Title
Oral Dexamethasone Versus Oral Prednisone in Children Hospitalized With Asthma: A Randomized Control Study
Study Type
Interventional
2. Study Status
Record Verification Date
June 2019
Overall Recruitment Status
Terminated
Why Stopped
insufficient number of participants met the enrollment criteria.
Study Start Date
March 20, 2017 (Actual)
Primary Completion Date
August 29, 2017 (Actual)
Study Completion Date
August 29, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Florida
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Asthma is the most common chronic disease of children. A short (3-5 day) course of a short-acting steroid such as Prednisone or Prednisolone has long been the standard of care for asthma exacerbation. Dexamethasone efficacy in asthma exacerbation has been studied in the outpatient setting and was found to be as effective as Prednisone. Dexamethasone has the advantage of shorter course, more compliance, and more tolerable. This has led many emergency departments to provide a 1-2 dose course of Dexamethasone on discharge. Thus, many inpatients have received a first dose of Dexamethasone prior to reaching the inpatient unit, leading to confusion about the best plan for these patients. Many hospitalist pediatricians continue to give a 5-day total course with Prednisone, but some patients have begun to receive a second dose of Dexamethasone 24 hours after the first dose. To our knowledge, no studies have been done to compare the efficacy of these two protocols in pediatric patients requiring hospitalization. The hypothesis is that a second dose of Dexamethasone is as effective as four additional days of Prednisone in hospitalized children with asthma exacerbation. This is an open label, randomized control study comparing these treatments in children age 2-18 hospitalized with asthma exacerbation who have received a first dose of Dexamethasone.
Detailed Description
Corticosteroids are the first-line therapy for managing acute asthma exacerbations. Studies have shown that systemic steroids effect decrease relapse and hospital admission. Due to its short half-life, Prednisone is usually given daily or twice daily for 3-5 days. It has been associated with poor compliance due it the prolonged course. Dexamethasone half-life is 36 - 72 hours.
Several studies have shown no difference in outcomes between 3-5 days of prednisone and different forms of dexamethasone, including single intramuscular dose or single oral dose or two oral doses 1 day apart. However, those studies were done in the emergency department (ED). Lack of response to initial asthma treatment in ED results in admission to the hospital, implying more severe exacerbation than those able to be discharged. Some clinician shift to oral prednisone once admitted to the floor for patients who have received Dexamethasone or not. Others have begin to complete the Dexamethasone course with one more dose of Dexamethasone 24 hour after the first dose. Dexamethasone has the advantage of compliance and tolerability, however, no studies investigated its efficacy in hospitalized patients. Such knowledge will improve patient's compliance and outcomes.
Sample size calculation: Primary outcome of return to normal activities within 3 days of discharge. Based on previous studies, it is estimated that 70% of the control group will achieve this goal. Based on a minimum absolute difference of 15%, and a power of 0.80, the sample size calculated to be 117 in each arm. Assuming 20% lost to follow up, it is intended to recruit 150 in each arm (total 300 subjects).
Statistical Analysis: Demographics will be analyzed to ensure the experimental and control groups are equivalent at baseline. All proportions will be tested with Chi-square or Fisher exact test and two-sample T-test will be used for continuous variables. α = 0.05 will be used for all hypothesis tests. Interim analysis will be performed monthly and the study will be halted if any safety concerns arise. The Center for Health Equity and Quality Research (CHEQR) will help with statistical analysis
Data Safety and Monitoring Plan: The study PI and co-investigator will meet and review the collected data on a monthly basis and identify any interim results that may require a change of study protocol. Information that may affect subjects' safety will be communicated to appropriate parties in a timely fashion.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma, Status Asthmaticus, Wheezes
Keywords
Prednisone, Dexamethasone, Asthma exacerbation, Hospitalized
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
6 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Dexamethasone
Arm Type
Experimental
Arm Description
Dexamethasone arm: will receive second dose of oral Dexamethasone 0.6 mg/kg/dose max of 16 mg, 24 hour from the first dose given in emergency department.
Arm Title
Prednisone
Arm Type
Active Comparator
Arm Description
Prednisone arm: will receive oral Prednisone 1mg/kg with max of 30 mg twice daily starting 24 hours after the Dexamethasone dose given in emergency department for 8 additional doses.
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Other Intervention Name(s)
Decadron
Intervention Description
at 24 hours from the first Dexamethasone dose given in ED.
Intervention Type
Drug
Intervention Name(s)
Prednisone
Other Intervention Name(s)
Orapred
Intervention Description
at 24 hours from the first Dexamethasone dose given in ED.
Primary Outcome Measure Information:
Title
Return to normal activity (Patient Self-Assessment Score)
Description
Proportion of patients who have returned to normal activity
Time Frame
3 days after discharge
Secondary Outcome Measure Information:
Title
Relapse ( ED visit or unscheduled physician visit)
Description
Proportion of patients with unscheduled primary care physician visits, emergency department or hospital admission
Time Frame
2 weeks after discharge
Title
Albuterol use (Patient Self-Assessment Score)
Description
Proportion of patients with of ongoing albuterol use (based on validated self-reporting tool)
Time Frame
2 weeks after discharge
Title
Asthma symptoms (Patient Self-Assessment Score)
Description
Patient self assessment score at 2 weeks after discharge
Time Frame
2 weeks after discharge
10. Eligibility
Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Signed informed consent by legal guardian
Age 2 to 18 years old
Admission to the floor with acute asthma exacerbation.
Received single dose of oral Dexamethasone
Initial Pediatric Asthma Score (PAS) of 8 or higher.
Exclusion Criteria:
Admission to PICU
Recent steroid use (within 1 month)
Cardiac disorder, chronic respiratory illness (BPD or CF)
Stridor
Bacterial Pneumonia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeffrey C Winer, MD
Organizational Affiliation
Universiry of Florida, College of Medicine Jacksonville
Official's Role
Principal Investigator
Facility Information:
Facility Name
Wolfson Children Hospital
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32207
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
17983880
Citation
National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94-138. doi: 10.1016/j.jaci.2007.09.043. Erratum In: J Allergy Clin Immunol. 2008 Jun;121(6):1330.
Results Reference
background
PubMed Identifier
24515516
Citation
Keeney GE, Gray MP, Morrison AK, Levas MN, Kessler EA, Hill GD, Gorelick MH, Jackson JL. Dexamethasone for acute asthma exacerbations in children: a meta-analysis. Pediatrics. 2014 Mar;133(3):493-9. doi: 10.1542/peds.2013-2273. Epub 2014 Feb 10.
Results Reference
background
PubMed Identifier
11445789
Citation
Qureshi F, Zaritsky A, Poirier MP. Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma. J Pediatr. 2001 Jul;139(1):20-6. doi: 10.1067/mpd.2001.115021.
Results Reference
background
PubMed Identifier
17636617
Citation
Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD000195. doi: 10.1002/14651858.CD000195.pub2.
Results Reference
background
PubMed Identifier
15502653
Citation
Butler K, Cooper WO. Adherence of pediatric asthma patients with oral corticosteroid prescriptions following pediatric emergency department visit or hospitalization. Pediatr Emerg Care. 2004 Nov;20(11):730-5. doi: 10.1097/01.pec.0000144914.78124.6f.
Results Reference
background
PubMed Identifier
15634032
Citation
Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98. doi: 10.2165/00003088-200544010-00003.
Results Reference
background
PubMed Identifier
10700684
Citation
Gries DM, Moffitt DR, Pulos E, Carter ER. A single dose of intramuscularly administered dexamethasone acetate is as effective as oral prednisone to treat asthma exacerbations in young children. J Pediatr. 2000 Mar;136(3):298-303. doi: 10.1067/mpd.2000.103353.
Results Reference
background
PubMed Identifier
9350159
Citation
Klig JE, Hodge D 3rd, Rutherford MW. Symptomatic improvement following emergency department management of asthma: a pilot study of intramuscular dexamethasone versus oral prednisone. J Asthma. 1997;34(5):419-25. doi: 10.3109/02770909709055384.
Results Reference
background
PubMed Identifier
17726409
Citation
Gordon S, Tompkins T, Dayan PS. Randomized trial of single-dose intramuscular dexamethasone compared with prednisolone for children with acute asthma. Pediatr Emerg Care. 2007 Aug;23(8):521-7. doi: 10.1097/PEC.0b013e318128f821.
Results Reference
background
PubMed Identifier
17198210
Citation
Altamimi S, Robertson G, Jastaniah W, Davey A, Dehghani N, Chen R, Leung K, Colbourne M. Single-dose oral dexamethasone in the emergency management of children with exacerbations of mild to moderate asthma. Pediatr Emerg Care. 2006 Dec;22(12):786-93. doi: 10.1097/01.pec.0000248683.09895.08.
Results Reference
background
PubMed Identifier
18467673
Citation
Greenberg RA, Kerby G, Roosevelt GE. A comparison of oral dexamethasone with oral prednisone in pediatric asthma exacerbations treated in the emergency department. Clin Pediatr (Phila). 2008 Oct;47(8):817-23. doi: 10.1177/0009922808316988. Epub 2008 May 8.
Results Reference
background
PubMed Identifier
12542074
Citation
National Asthma Education and Prevention Program. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics--2002. J Allergy Clin Immunol. 2002 Nov;110(5 Suppl):S141-219. No abstract available. Erratum In: J Allergy Clin Immunol. 2003 Mar;111(3):466.
Results Reference
background
Learn more about this trial
Steroids in Children Hospitalized With Asthma
We'll reach out to this number within 24 hrs